Sickle Cell Disease and Stroke
Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk f...
Gespeichert in:
Veröffentlicht in: | Pediatric neurology 2019-06, Vol.95, p.34-41 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 41 |
---|---|
container_issue | |
container_start_page | 34 |
container_title | Pediatric neurology |
container_volume | 95 |
creator | Hirtz, Deborah Kirkham, Fenella J. |
description | Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease. |
doi_str_mv | 10.1016/j.pediatrneurol.2019.02.018 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2204694108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0887899418313055</els_id><sourcerecordid>2204694108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</originalsourceid><addsrcrecordid>eNqNkE1Lw0AQhhdRbK3-hRLw4iVx9iPJLp6k1g8oeKiel-1mAtumSd1NBP-9W1oFb57m8rzvzDyEXFPIKNDidp3tsHKm9y0OvmsyBlRlwDKg8oSMqSx5mtMcTskYpCxTqZQYkYsQ1gCQKybOyYiDEpKKckymS2c3DSYzbJrkwQU0ARPTVsmy990GL8lZbZqAV8c5Ie-P87fZc7p4fXqZ3S9SK3jRpxWzpeWFpJznFphkigI3sixZwascchCWMoMmN5KvUKyUrEsmRAyLWhag-ITcHHp3vvsYMPR664KNN5kWuyFoxkAUSlCQEb07oNZ3IXis9c67rfFfmoLeC9Jr_UeQ3gvSwHQUFNPT46JhtcXqN_tjJALzA4Dx3U-HXgfrsLWx0aPtddW5fy36BiGne6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2204694108</pqid></control><display><type>article</type><title>Sickle Cell Disease and Stroke</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hirtz, Deborah ; Kirkham, Fenella J.</creator><creatorcontrib>Hirtz, Deborah ; Kirkham, Fenella J.</creatorcontrib><description>Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease.</description><identifier>ISSN: 0887-8994</identifier><identifier>EISSN: 1873-5150</identifier><identifier>DOI: 10.1016/j.pediatrneurol.2019.02.018</identifier><identifier>PMID: 30948147</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anemia, Sickle Cell - complications ; Anemia, Sickle Cell - diagnostic imaging ; Anemia, Sickle Cell - therapy ; Blood Transfusion - trends ; Cerebral blood flow ; Cerebrovascular Circulation - physiology ; Hemorrhage ; Humans ; Hydroxyurea ; Hydroxyurea - therapeutic use ; Silent infarction ; Stroke - diagnostic imaging ; Stroke - etiology ; Stroke - therapy ; Transcranial Doppler ; Transfusion therapy ; Ultrasonography, Doppler, Transcranial - trends</subject><ispartof>Pediatric neurology, 2019-06, Vol.95, p.34-41</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</citedby><cites>FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</cites><orcidid>0000-0002-2443-7958</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0887899418313055$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30948147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirtz, Deborah</creatorcontrib><creatorcontrib>Kirkham, Fenella J.</creatorcontrib><title>Sickle Cell Disease and Stroke</title><title>Pediatric neurology</title><addtitle>Pediatr Neurol</addtitle><description>Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease.</description><subject>Anemia, Sickle Cell - complications</subject><subject>Anemia, Sickle Cell - diagnostic imaging</subject><subject>Anemia, Sickle Cell - therapy</subject><subject>Blood Transfusion - trends</subject><subject>Cerebral blood flow</subject><subject>Cerebrovascular Circulation - physiology</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Hydroxyurea</subject><subject>Hydroxyurea - therapeutic use</subject><subject>Silent infarction</subject><subject>Stroke - diagnostic imaging</subject><subject>Stroke - etiology</subject><subject>Stroke - therapy</subject><subject>Transcranial Doppler</subject><subject>Transfusion therapy</subject><subject>Ultrasonography, Doppler, Transcranial - trends</subject><issn>0887-8994</issn><issn>1873-5150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1Lw0AQhhdRbK3-hRLw4iVx9iPJLp6k1g8oeKiel-1mAtumSd1NBP-9W1oFb57m8rzvzDyEXFPIKNDidp3tsHKm9y0OvmsyBlRlwDKg8oSMqSx5mtMcTskYpCxTqZQYkYsQ1gCQKybOyYiDEpKKckymS2c3DSYzbJrkwQU0ARPTVsmy990GL8lZbZqAV8c5Ie-P87fZc7p4fXqZ3S9SK3jRpxWzpeWFpJznFphkigI3sixZwascchCWMoMmN5KvUKyUrEsmRAyLWhag-ITcHHp3vvsYMPR664KNN5kWuyFoxkAUSlCQEb07oNZ3IXis9c67rfFfmoLeC9Jr_UeQ3gvSwHQUFNPT46JhtcXqN_tjJALzA4Dx3U-HXgfrsLWx0aPtddW5fy36BiGne6Q</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Hirtz, Deborah</creator><creator>Kirkham, Fenella J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2443-7958</orcidid></search><sort><creationdate>201906</creationdate><title>Sickle Cell Disease and Stroke</title><author>Hirtz, Deborah ; Kirkham, Fenella J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anemia, Sickle Cell - complications</topic><topic>Anemia, Sickle Cell - diagnostic imaging</topic><topic>Anemia, Sickle Cell - therapy</topic><topic>Blood Transfusion - trends</topic><topic>Cerebral blood flow</topic><topic>Cerebrovascular Circulation - physiology</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Hydroxyurea</topic><topic>Hydroxyurea - therapeutic use</topic><topic>Silent infarction</topic><topic>Stroke - diagnostic imaging</topic><topic>Stroke - etiology</topic><topic>Stroke - therapy</topic><topic>Transcranial Doppler</topic><topic>Transfusion therapy</topic><topic>Ultrasonography, Doppler, Transcranial - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirtz, Deborah</creatorcontrib><creatorcontrib>Kirkham, Fenella J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirtz, Deborah</au><au>Kirkham, Fenella J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sickle Cell Disease and Stroke</atitle><jtitle>Pediatric neurology</jtitle><addtitle>Pediatr Neurol</addtitle><date>2019-06</date><risdate>2019</risdate><volume>95</volume><spage>34</spage><epage>41</epage><pages>34-41</pages><issn>0887-8994</issn><eissn>1873-5150</eissn><abstract>Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30948147</pmid><doi>10.1016/j.pediatrneurol.2019.02.018</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2443-7958</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0887-8994 |
ispartof | Pediatric neurology, 2019-06, Vol.95, p.34-41 |
issn | 0887-8994 1873-5150 |
language | eng |
recordid | cdi_proquest_miscellaneous_2204694108 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Anemia, Sickle Cell - complications Anemia, Sickle Cell - diagnostic imaging Anemia, Sickle Cell - therapy Blood Transfusion - trends Cerebral blood flow Cerebrovascular Circulation - physiology Hemorrhage Humans Hydroxyurea Hydroxyurea - therapeutic use Silent infarction Stroke - diagnostic imaging Stroke - etiology Stroke - therapy Transcranial Doppler Transfusion therapy Ultrasonography, Doppler, Transcranial - trends |
title | Sickle Cell Disease and Stroke |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T20%3A43%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sickle%20Cell%20Disease%20and%20Stroke&rft.jtitle=Pediatric%20neurology&rft.au=Hirtz,%20Deborah&rft.date=2019-06&rft.volume=95&rft.spage=34&rft.epage=41&rft.pages=34-41&rft.issn=0887-8994&rft.eissn=1873-5150&rft_id=info:doi/10.1016/j.pediatrneurol.2019.02.018&rft_dat=%3Cproquest_cross%3E2204694108%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2204694108&rft_id=info:pmid/30948147&rft_els_id=S0887899418313055&rfr_iscdi=true |